A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)

A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)

Background: The efficacy of the viral clearance and clinical outcomes of favipiravir (FPV) in outpatients being treated for coronavirus disease 2019 (COVID-19) is unclear. Ivermectin (IVM), niclosamide (NCL), and FPV demonstrated synergistic effects in vitro for exceed 78% inhibiting severe acute re...

Full description

Bibliographic Details
Main Authors: Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Panisadee Avirutnan, Kunlakanya Jitobaom, Prasert Auewarakul
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Journal of Infection and Public Health
Subjects:
Favipiravir
Ivermectin
Niclosamide
COVID-19
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034124001060

Internet

http://www.sciencedirect.com/science/article/pii/S1876034124001060

Similar Items